September 340Buzz: Pharma pushback continues
/ by Lisa Scholz, PharmD, FACHE, Head of Industry Relations
A deeper dive into strategies pharmaceutical companies have been cooking up to curtail the 340B program and skirt payment requirements.
HRSA audits go virtual for COVID-19: What covered entities need to know
/ by Ivy Espendez, Director, 340B Compliance and Audits
In response to the COVID-19 pandemic, HRSA’s Office of Pharmacy Affairs has made a number of adjustments to its guidelines for the 340B drug pricing program for stakeholders.
August 340Buzz: When it rains, it pours
/ by Lisa Scholz, PharmD, FACHE, Head of Industry Relations
We take a deeper dive into the moves pharma has been making and the executive order affecting FQHCs that we mentioned in previous blogs last month, discuss the long-awaited court decision about the Medicare part B reimbursement cuts, and we also take a look at HRSA’s new registration and recertification requirements.
When it comes to 340B management and compliance, software training makes all the difference
/ by Dionne Bourque, Marketing Specialist II
Our new Foundations Certificate program is a method of training that is interactive and application based—meaning the training provides scenarios to support optimal use of all of Sentry’s tools in a peer setting.
340B past, present, and future in the era of COVID-19 – moving forward after a watershed moment
/ by Lisa Scholz, PharmD, FACHE, Head of Industry Relations
For almost 30 years, the 340B program has proven to be dynamic and versatile. It has adapted to the changing healthcare landscape before and will do so again.
The impact of unpaid medication claims and what you can do to take back control
/ by Jami Hernandez, Product Manager
There’s no understating the impact that delayed or denied claims can have on your organization’s bottom line – particularly claims in which clinicians at hospitals and health systems administer medication as part of the treatment plan.
New executive orders intended to lower drug prices take aim at 340B
/ by Lisa Scholz, PharmD, FACHE, Head of Industry Relations
On Friday, June 24, President Trump signed four executive orders aimed at lowering the high cost of drugs in the US. The orders deal with issues including reducing insulin and EpiPen prices, the importation of drugs from Canada, curbing rebates…
July 340Buzz bonus edition: Pharma stirs the pot
/ by Lisa Scholz, PharmD, FACHE, Head of Industry Relations
This month, we bring you a bonus 340Buzz report in addition to our monthly blog post. Three pharma companies have attempted to stir the pot when it comes to what’s within their rights regarding the 340B program.
Merck and Sanofi release manufacturer…
July 340Buzz: Drug prices, program oversight and 340B eligibility
/ by Lisa Scholz, PharmD, FACHE, Head of Industry Relations
This month, HHS distributes $4 billion in additional relief to safety-net hospitals, AHA loses the price transparency rule legal battle, and a new Senate bill aims to protect 340B eligibility during COVID-19.
Price transparency moves ahead
In…
Unique 340B challenges for FQHCs and how to overcome them
/ by Lisa Scholz, PharmD, FACHE, Head of Industry Relations
Federally Qualified Health Centers (FQHCs) operate on a not-for-profit basis and serve a disproportionate share of our nation’s vulnerable population – patients who often struggle with interconnected disparities that affect their health,…
